Altimmune, Inc. (ALT)

Altimmune's stock price has experienced significant fluctuations over the past six months, decreasing by 56.21% year-to-date and over the last six months. Key events impacting the stock include clinical trial data announcements, public offerings, earnings reports, FDA Breakthrough Therapy Designation for pemvidutide, and the Annual General Meeting. The stock has seen rallies leading up to data readouts, followed by drops if the market reception is unfavorable. Public offerings have introduced dilution risk, and earnings reports have sometimes been followed by modest declines. The company received FDA Breakthrough Therapy Designation for pemvidutide in March 2026 and held its Annual General Meeting on April 16, 2026.

The provided search results do not contain specific information regarding demand seasonality for Altimmune, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its primary activities revolve around research, development, and clinical trials of drug candidates rather than the commercial sale of established products. Therefore, traditional demand seasonality is unlikely to be a significant factor for Altimmune at its current stage of development.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases, obesity, and metabolic disorders. Their lead product candidate, pemvidutide, is in Phase 3 clinical trials for MASH and is also being developed for alcohol use disorder and alcohol-associated liver disease. Pemvidutide activates GLP-1 receptors to suppress appetite and reduce cravings, while glucagon receptor activation impacts the liver by reducing fat, inflammation, and fibrosis.

Altimmune, Inc. is headquartered in Gaithersburg, Maryland, United States. The company's operations and clinical trials are primarily focused within the United States.

Specific information detailing Altimmune, Inc.'s brand reputation was not found in the provided search results. However, the company's reputation is likely closely tied to the progress and outcomes of its clinical trials for pemvidutide. Positive clinical trial results and regulatory designations would generally enhance its reputation, while setbacks could negatively impact it. Analyst ratings currently give Altimmune a "Moderate Buy" consensus.

Institutional investors are significant owners of Altimmune, holding a substantial majority of the shares. As of May 6, 2026, Altimmune, Inc. has 196 institutional owners and shareholders holding a total of 68,293,622 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Individual investors hold a considerable percentage of the company's stake, while insiders own a smaller percentage. WallStreetZen reports different ownership percentages, with Prescott Group Capital Management LLC being the largest individual Altimmune shareholder.